Vitamin d Level and it's Association With Disease Activity in Egyptian Rheumatoid Arthritis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

130 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-01

Study Completion Date

2023-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vitamin D level and its association with disease activity in Egyptian Rheumatoid arthritis (RA) patients

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vitamin D as a Key Player in Rheumatoid Arthritis

NCT04344405

the Immunomodulatory Effect

COMPLETED PHASE3

Impact of Vitamin D in Rheumatoid Arthritis

NCT06716476

Rheumatic Arthritis

COMPLETED PHASE4

Omega-3 and Vitamin E Supplementation in Patients With Rheumatoid Arthritis

NCT00399282

Rheumatoid Arthritis

COMPLETED PHASE1

Role of Vitamin D3 Supplementation With Conventional Synthetic Disease Modifying Antirheumatic Drugs(csDMARD) in Rheumatoid Arthritis Patients

NCT05078502

Rheumatoid Arthritis

COMPLETED NA

L-carnitine Supplementation in Rheumatoid Arthritis Patients

NCT06753565

Rheumatoid Arthritis (RA)

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects about 1% of the human population. Its incidence increases between 25 and 55 years and is the most common type of chronic inflammatory arthritis . It affects joints bilaterally with synovial hyperplasia, cartilage erosion, bone destruction, and progressive loss of function . also characterized by systemic features and joint involvement. It can lead to significant morbidity and mortality so early diagnosis and proper treatment are crucial in decreasing the burden of this disease . According to the World Health Organization mortality database of 31 countries, RA accounts for almost 18% of all deaths caused by different types of arthritis and other musculoskeletal diseases, but the exact cause of RA remains unknown

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis (RA)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

65 rheumatoid arthritis patient

Vitamin d effect on rheumatoid arthritis activity on 65 rheumatoid arthritis patients and 65 healthy population

Vit D

Intervention Type DRUG

Vit D

65 healthy population

Vitamin d effect on rheumatoid arthritis activity on 65 rheumatoid arthritis patients and 65 healthy population

Vit D

Intervention Type DRUG

Vit D

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vit D

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Both males and females in the age group of 1875 years having RA according to the American College of Rheumatology European League Against Rheumatism 2010 criteria (Meena et al., 2018). Will enrolled in this study

Exclusion Criteria

* Patients with malnutrition, hepatic and renal dysfunction, hyperparathyroidism, hyperthyroidism, diabetes mellitus, and patients on Vitamin D supplementation in the past 6 months or on medications that can affect bone and Vitamin D metabolism (anticonvulsants, diuretics, and thyroxin) were excluded from this study.
* Patients with overlap syndrome
* known allergy to DMARDs, 1,25 dihydroxy vitamin D3 or calcium supplements

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes